The World Health Organization (WHO) has prequalified South Korean drugmaker Celltrion’s biosimilar version of rituximab, the second product achieving that status under a biosimilar prequalification ...

The US Food and Drug Administration (FDA) on Wednesday approved Celltrion and Teva’s Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with ...

Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes. The combination regimen rituximab ...

On July 12, Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s) announced that the U.S. Food and Drug Administration (FDA) accepted for review its Biologics License Application (BLA) for DRL_RI, a biosimilar ...

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

On November 17, 2023, Genentech, Hoffman-La Roche, and Biogen (collectively “plaintiffs”) filed a complaint in the federal district court for the District of New Jersey against Dr. Reddy’s ...

Dublin, May 01, 2026 (GLOBE NEWSWIRE)-- The "Rituximab Biosimilars Market Report 2026" has been added to ResearchAndMarkets.com's offering. The rituximab biosimilars market is experiencing rapid ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or ...

Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Rituximab Biosimilars Global Market Report 2022: By Application, By Distribution, By Route" report has been added to ResearchAndMarkets.com's offering.